Human IFN-Alpha (interferon alpha) occurs naturally as more than a dozen subtypes, each from a distinct gene of the IFNA locus, with over 85% amino acid sequence identity between them but measurable differences in antiviral, antiproliferative, and immunomodulatory potency. PBL Assay Science offers the two most studied subtypes (alpha 2a and 2b) for therapeutic applications, twelve additional native subtypes for subtype-specificity research, a cross-species Universal Type I IFN hybrid protein, and a 12-subtype Sampler Set for screening multiple subtypes side by side. Subtypes carry two overlapping naming systems, a numbered one (2a, 8, 10) and an older lettered one (alpha A, alpha B2, alpha C). Click to see Human IFN-Alpha Subtype nomenclature table.
IFN-Alpha Mechanism and Therapeutic Application
Cells produce IFN-alpha in response to viral infection and immune stimulators. It binds the IFNAR1/IFNAR2 receptor, triggering JAK1/TYK2 and STAT1/STAT2 phosphorylation; the resulting ISGF3 complex enters the nucleus and induces antiviral genes like PKR and Mx proteins.
Alpha 2a and 2b pioneered interferon therapeutics, establishing treatments for Hairy Cell Leukemia and Hepatitis B/C, and remain the field's gold-standard research and comparator reagents today. The other native subtypes, while less characterized, offer rich opportunity for comparative research into their distinct activities.